viagenpumatucel-L (HS-110) / Scorpius Holdings  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
viagenpumatucel-L (HS-110) / NightHawk Biosci
NCT01504542: Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Withdrawn
2a
0
US
HS110 vaccine, Placebo
Heat Biologics
Non-small Cell Lung Cancer
12/13
12/13
NCT02117024: A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Terminated
2
66
US
Viagenpumatucel-L, HS-110, Metronomic Cyclophosphamide, Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
Heat Biologics
Non Small Cell Lung Cancer
12/17
04/18
DURGA, NCT02439450: A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Checkmark Interim data from DURGA trial in combination with HS110
Feb 2018 - Feb 2018: Interim data from DURGA trial in combination with HS110
Completed
1b/2
121
US
Viagenpumatucel-L, HS-110, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Pemetrexed, Alimta
Heat Biologics
Non-small Cell Lung Cancer
05/21
11/22

Download Options